ImmunityBio, Inc. IBRX
Set alert
7.95 USD -0.34 -4.10%
At close
7.97 +0.02 +0.25%
Pre-market · Nov 3, 6:25 AM ET
7.93 Day range 8.39
1.95 52-week range 12.43
- YTD
- +301.52%
- 1 year
- +251.77%
- Open
- 8.32
- Prev close
- 8.29
- Mkt cap
- 8.43B
- Vol
- 9.05M
- Avg vol
- 11.48M
- EPS
- -0.96
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 7.93
- High
- 8.39
- Forward P/E
- -108.41
- Beta
- 0.17
- Short ratio
- 7.96
- Inst. own
- 19.81%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 8.71
- 200-d avg
- 7.90
- 1y target
- 14.25
3M chart
Events in this range
- Aug 4, 2026Earnings: -0.22; estimate -0.08; surprise -175%
- Oct 15, 2026Rating: HC Wainwright & Co. · Buy → Buy
- Oct 15, 2026Rating: Jefferies · Buy → Buy
Signals (23)
| Name | Date | Ago |
|---|---|---|
| SMA: Bearish | Oct 30, 2026 | 3 days ago |
| SMA: Bullish | Oct 28, 2026 | 5 days ago |
| SMA: Bearish | Oct 22, 2026 | 1 week ago |
| SMA: Bullish | Oct 20, 2026 | 1 week ago |
| SMA: Bearish | Oct 19, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 19, 2026 | 2 weeks ago |
| MACD: Sell Signal | Oct 16, 2026 | 2 weeks ago |
| RSI: Overbought | Oct 2, 2026 | 1 month ago |
| MACD: Buy Signal | Sep 17, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bullish | Sep 11, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| SMA: Bearish | Sep 10, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 10, 2026 | 1 month ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 14, 2026 | 2 months ago |
| SMA: Bullish | Aug 12, 2026 | 2 months ago |
Newest 20 of 23.
Financial health
Altman Z-Score
-11.02 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
3 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
C2 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -5.2×
FY 2016 5y median -4.9× FY 2025
P/S 16.1×
FY 2016 5y median 2534× FY 2025
P/B -3.6×
FY 2016 5y median -4.3× FY 2025
P/FCF -5.9×
FY 2016 5y median -5.9× FY 2025
EV/EBITDA -11.7×
FY 2016 5y median -8.1× FY 2025
EV/Sales 23.0×
FY 2016 5y median 3031× FY 2025
FCF Yield -17.0%
FY 2016 5y median -17.0% FY 2025
Profitability
Gross Margin 99.3%
FY 2016 5y median 100.0% FY 2025
Operating Margin -226.0%
FY 2016 5y median -35361.9% FY 2025
Net Margin -310.2%
FY 2016 5y median -37129.6% FY 2025
ROE 70.3%
FY 2016 5y median 93.1% FY 2025
ROIC -56.9%
FY 2016 5y median -82.1% FY 2025
ROA -70.0%
FY 2016 5y median -108.0% FY 2025
Growth (YoY)
Revenue 668.3%
FY 2016 FY 2025
Operating Income 25.6%
FY 2016 FY 2025
EPS (diluted) 38.7%
FY 2016 FY 2025
Free Cash Flow 22.4%
FY 2016 FY 2025
Financial Health
Current Ratio 5.1×
FY 2016 5y median 3.4× FY 2025
Quick Ratio 5.1×
FY 2016 5y median 3.2× FY 2025
Debt / Equity -1.8×
FY 2016 5y median -1.6× FY 2025
Net Debt / EBITDA -3.5×
FY 2016 5y median -1.4× FY 2025
Interest Coverage -2.3×
FY 2016 5y median -4.2× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31
